Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Milone

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 23, 2009
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivoMichael C Milone, Jonathan D Fish, Carmine Carpenito, et al.
The Journal of Experimental Medicine|May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levelsMeidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
The Journal of Clinical Investigation|August 21, 2020
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgarisJinmin Lee, Daniel K Lundgren, Xuming Mao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Blood Advances|May 12, 2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cellsTina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, et al.
Blood Cancer Discovery|August 26, 2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaKavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, et al.
Immunity|August 27, 2017
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T CellsOmkar U Kawalekar, Roddy S O' Connor, Joseph A Fraietta, et al.
British Journal of Haematology|March 13, 2021
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapyLuca Bernabei, Lifeng Tian, Alfred L Garfall, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media DesignSaba Ghassemi, Francisco J Martinez-Becerra, Alyssa M Master, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 23, 2009
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivoMichael C Milone, Jonathan D Fish, Carmine Carpenito, et al.
The Journal of Experimental Medicine|May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levelsMeidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
The Journal of Clinical Investigation|August 21, 2020
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgarisJinmin Lee, Daniel K Lundgren, Xuming Mao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Blood Advances|May 12, 2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cellsTina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, et al.
Blood Cancer Discovery|August 26, 2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaKavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, et al.
Immunity|August 27, 2017
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T CellsOmkar U Kawalekar, Roddy S O' Connor, Joseph A Fraietta, et al.
British Journal of Haematology|March 13, 2021
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapyLuca Bernabei, Lifeng Tian, Alfred L Garfall, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media DesignSaba Ghassemi, Francisco J Martinez-Becerra, Alyssa M Master, et al.
Pageof 11